| 28.02 -0.59 (-2.06%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.32 | 1-year : | 41.25 |
| Resists | First : | 30.23 | Second : | 35.32 |
| Pivot price | 26.44  |
|||
| Supports | First : | 23.76 | Second : | 19.76 |
| MAs | MA(5) : | 28.87 |
MA(20) : | 26.03 |
| MA(100) : | 20.04 |
MA(250) : | 18.61 |
|
| MACD | MACD : | 1.4  |
Signal : | 1.2 |
| %K %D | K(14,3) : | 82 |
D(3) : | 89 |
| RSI | RSI(14): 57.9 |
|||
| 52-week | High : | 30.47 | Low : | 10.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ EWTX ] has closed below upper band by 31.9%. Bollinger Bands are 89.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 28.51 - 28.66 | 28.66 - 28.79 |
| Low: | 27.26 - 27.46 | 27.46 - 27.62 |
| Close: | 27.73 - 28.02 | 28.02 - 28.27 |
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Fri, 23 Jan 2026
Insider Sell: Badreddin Edris Sells 115,471 Shares of Edgewise Therapeutics Inc (EWTX) - GuruFocus
Fri, 23 Jan 2026
Edgewise Therapeutics (NASDAQ:EWTX) Director Sells $3,399,466.24 in Stock - MarketBeat
Wed, 21 Jan 2026
A Look At Edgewise Therapeutics (EWTX) Valuation After Detailed Late Stage Pipeline Milestone Update - simplywall.st
Wed, 21 Jan 2026
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Mon, 19 Jan 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Eastern Progress
Sat, 17 Jan 2026
Is Edgewise Therapeutics (EWTX) Quietly Redefining Its Risk Profile With an Integrated Muscle-Heart Strategy? - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 106 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 107.4 (%) |
| Shares Short | 11,690 (K) |
| Shares Short P.Month | 11,150 (K) |
| EPS | -1.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.28 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.7 % |
| Return on Equity (ttm) | -30.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.69 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -132 (M) |
| Levered Free Cash Flow | -80 (M) |
| PE Ratio | -17.85 |
| PEG Ratio | 0 |
| Price to Book value | 5.3 |
| Price to Sales | 0 |
| Price to Cash Flow | -22.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|